CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 15.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,997 shares of the company’s stock after purchasing an additional 4,650 shares during the period. Privium Fund Management B.V.’s holdings in CRISPR Therapeutics were worth $1,377,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Capital Market Strategies LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $461,000. KBC Group NV raised its stake in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Geode Capital Management LLC lifted its position in CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after acquiring an additional 35,196 shares during the period. State Street Corp lifted its position in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares during the period. Finally, ARK Investment Management LLC grew its stake in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In other news, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock worth $1,608,243 over the last three months. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on CRSP shares. HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Bank of America cut their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Needham & Company LLC restated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada lowered their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $40.97 on Wednesday. The firm has a fifty day moving average of $43.04 and a 200 day moving average of $45.47. The firm has a market cap of $3.51 billion, a PE ratio of -9.38 and a beta of 1.76. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.